Navigation Links
New HAE Drug Candidate from Dyax Produced by Laureate Biopharma
Date:8/26/2013

PRINCETON, N.J., Aug. 26, 2013 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema (HAE).  The drug candidate, known as DX-2930, is a fully human IgG antibody designed to prevent HAE attacks by inhibition of plasma kallikrein. Dyax, a biopharmaceutical company focused on HAE and other plasma kallikrein disorders, recently announced the start of a Phase 1 clinical trial evaluating the safety and tolerability of DX-2930.

In working with the cell line producing DX-2930, Laureate's scientists were able to successfully scale-up and manufacture a high-titer antibody process. This process was amendable to cGMP production in both stainless-steel and single-use bioreactors. Application of Laureate's platform downstream process for IgG antibodies led to high protein recovery and purity. Aseptic filling, a routine operation at Laureate, produced the clinical drug product in 98% yield. Finally, careful project management of the program by both companies resulted in the successful release of bulk drug substance.

"Entry into human subjects is an important milestone for the DX-2930 development program," said Gustav Christensen, President and CEO of Dyax.  "It was a pleasure to work with Laureate's scientific and program management team.  This valuable partnership has enabled us to advance this fully human monoclonal antibody into the clinic and closer toward our goal of a new therapeutic for the prevention of HAE attacks."

"This project showcased Laureate's scientific expertise in rapid development of efficient, high-yielding processes for clinical production of therapeutic antibodies," noted Michiel E. Ultee, Ph.D., Laureate's Chief Scientific Officer. "Our scientists have produced a wide variety of antibodies for more than 30 years, including IgG, IgM, fragmented (Fab & F(ab')2), conjugated, aglycosylated and domain-deleted antibodies."

About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit www.LBioS.com.

About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs.  The Company's key value drivers are the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Program (LFRP).

For additional information about Dyax, please visit www.dyax.com.

For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.

For more information, contact: Michiel E. Ultee, Ph.D., Chief Scientific Officer, Laureate Biopharma, at (609) 919-3390 or info@LBioS.com, or visit www.LBioS.com.


'/>"/>
SOURCE Laureate Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
4. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
5. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
6. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
7. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
8. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
9. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
10. Test Results Show Unprecedented Achievement for Marburg Drug Candidate
11. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting ... pm to present to graduate students exciting new and innovative hope research based on ... by The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) ...
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance Services, ... communities in the greater Chicago metropolitan area, is embarking on a charity drive ... in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & ... to families and business owners in North Central West Virginia, is embarking on ... to differently abled residents in the region. , The Stepping Stones organization offers ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Branches, Inc. has ... than $245,000 in grant funding to support its programs focused on providing opportunity to ... was awarded a grant by the Foundation of $15,000 to support its , Climb ...
(Date:6/22/2017)... ... 2017 , ... United Benefit Advisors (UBA), the nation’s leading ... its newest Partner Firm. Headquartered in Coconut Creek, Florida, Whipple & Company was ... benefit packages that strengthen the relationship between employer and employee. , “We are ...
Breaking Medicine News(10 mins):